Keryx Biopharmaceuticals Sets New 1-Year High at $18.03 (KERX)
Keryx Biopharmaceuticals (NASDAQ:KERX)’s share price hit a new 52-week high during mid-day trading on Tuesday , AnalystRatingsNetwork reports. The company traded as high as $18.03 and last traded at $17.80, with a volume of 2,468,438 shares. The stock had previously closed at $17.23.
A number of research firms have recently commented on KERX. Analysts at Maxim Group reiterated a “buy” rating on shares of Keryx Biopharmaceuticals in a research note on Tuesday. Separately, analysts at FBR Capital Markets initiated coverage on shares of Keryx Biopharmaceuticals in a research note on Wednesday, August 13th. They set a “market perform” rating and a $16.00 price target on the stock. Finally, analysts at Mizuho cut their price target on shares of Keryx Biopharmaceuticals from $32.00 to $30.00 in a research note on Friday, August 8th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $22.89.
The stock has a 50-day moving average of $15.4 and a 200-day moving average of $14.92. The company’s market cap is $1.647 billion. Keryx Biopharmaceuticals also was the recipient of unusually large options trading activity on Monday. Traders purchased 4,730 call options on the stock. This is an increase of approximately 289% compared to the typical volume of 1,215 call options.
Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its earnings results on Thursday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.01. During the same quarter in the previous year, the company posted ($0.14) earnings per share. Analysts expect that Keryx Biopharmaceuticals will post $-0.89 EPS for the current fiscal year.
Keryx Biopharmaceuticals, Inc (NASDAQ:KERX) is focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.